Key result
Early rivaroxaban undergoes testing versus warfarin for recurrent lesions and bleeding in AF-related acute stroke.
Why the study?
Patients with AF in the acute stage of ischemic stroke or TIA are at high risk of recurrent stroke, but the optimal anticoagulation strategy remains unclear due to bleeding concerns.
Does early anticoagulation with rivaroxaban reduce the composite of recurrent ischemic lesion and intracranial bleeding on MRI at four-weeks compared to warfarin in patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation?
RCT (n=196)
Open-label, blinded endpoint evaluation
randomized
Does early anticoagulation with rivaroxaban reduce the composite of recurrent ischemic lesion and intracranial bleeding on MRI at four-weeks compared to warfarin in patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation?
The Triple AXEL trial is designed to evaluate the feasibility and safety of early anticoagulation with rivaroxaban compared to warfarin in patients with acute ischemic stroke or TIA and nonvalvular atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Will evaluate early rivaroxaban feasibility versus warfarin post-stroke in AF; RCT data needed to guide anticoagulation timing.
RATIONALE: Patients with atrial fibrillation (AF) in the acute stage of ischemic stroke or transient ischemic attack (TIA) are at high risk of recurrent stroke, but the optimal anticoagulation strategy remains unclear due to the concern of intracranial bleeding. Novel oral anticoagulants compared to warfarin might be more safe and efficacious in patients suitable for early anticoagulation. AIMS: This trial is to evaluate the feasibility of early anticoagulation with rivaroxaban in acute ischemic stroke or TIA patients with nonvalvular AF. DESIGN: This is a randomized, open-label, blinded endpoint evaluation trial. Inclusion criteria are (1) nonvalvular AF, (2) presumed cardioembolic stroke or transient ischemic attack (TIA) confirmed by MRI within five-days from onset, and (3) mild to moderate stroke severity. We will randomize 196 patients to either rivaroxaban (10 mg once daily for five-days followed by 15 mg or 20 mg once daily) or dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving international normalized ratio of 1·7). The study is registered in ClinicalTrials.gov (NCT02042534). STUDY OUTCOMES: The primary endpoint is the composite of recurrent ischemic lesion and intracranial bleeding on MRI at four-weeks. Secondary endpoints are recurrent ischemic lesions, intracranial bleeding, major bleeding, major vascular events, four-week modified Rankin Scale score, and duration of hospitalization after randomization. DISCUSSION: The results of this proof-of-concept trial will guide go/no-go decision to a large phase 3 confirmatory trial.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2014) conducted an RCT in Acute ischemic stroke or TIA with nonvalvular AF (n=196). Rivaroxaban vs. Dose-adjusted warfarin (coadministration of aspirin 100 mg per day until achieving INR of 1.7) was evaluated on Composite of recurrent ischemic lesion and intracranial bleeding on MRI at four-weeks. The Triple AXEL trial is designed to evaluate early anticoagulation with rivaroxaban versus dose-adjusted warfarin in 196 patients with acute ischemic stroke or TIA and nonvalvular AF.
Synapse has enriched 10 related papers. Consider them for comparative context: